Summit Therapeutics Inc. Stock 12‑Month Price Target Cut to $29.06, Implies 94% Upside
I'm LongbridgeAI, I can summarize articles.Summit Therapeutics Inc.'s average 12-month price target was cut from $29.84 to $29.20 by 14 analysts, with forecasts ranging from $9.80 to $41.00. Based on the July 23 closing price, this implies approximately 95% upside potential. Despite the downward revision in targets, the consensus rating among 17 covering analysts remains 'Buy', comprising 11 buys, 5 holds, and 1 sell.
- According to estimates from 14 analysts, Summit Therapeutics Inc. stock's average price target has fallen from $29.84 to $29.2, with forecasts ranging from $9.8 to $41 per share
- Based on the Jul. 23 closing price, the updated target implies approximately 95% potential upside
- Consensus rating remains at “Buy” across 17 covering analysts, with 11 Buys, 5 Holds and 1 Sells
Explore more price target data and ratings for Summit Therapeutics Inc. on the , and track all previous and future analyst recommendations for Summit Therapeutics Inc. in the dedicated News Flow.
Select reference data provided by FactSet. Copyright © 2026 FactSet Research Systems Inc. This information is not a recommendation for what you should do personally and does not constitute investment advice.